DotBio Pte.
Latest round
- Series A
Last raised
- May 2019
Total raised
- $3M
Investors
- 3
About DotBio Pte.
DotBio Pte.Founded in 2017 and headquartered in Singapore, DotBio Pte. Ltd. focuses on innovative antibody therapies.DotBio specializes in the development of next-generation antibody therapies utilizing its proprietary DotBody technology platform. This innovative platform is based on modular design, facilitating the prefabrication of antibody modules with specific functions. DotBio combines these modules on demand to create multi-functional antibodies, including bi- and tri-specific antibodies, antibody-drug conjugates (ADCs), and intracellular antibodies. This high-throughput process accelerates the development timeline, enabling the generation of complex antibody products within months.30. The company generates revenue through partnerships and B2B transactions with pharmaceutical companies and research institutions, providing customized antibody therapies and related services.In August 2023, DotBio Pte. Ltd.6 mn to scale operations and commence pre-clinical, chemical manufacturing, and control studies to validate its therapeutic drug candidates.
Who invested in DotBio Pte.
3 investors across 1 round
See all investors in DotBio Pte.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 2, 2019
Amount
$3M
Investors
Questions about DotBio Pte.
Who invested in DotBio Pte.?
DotBio Pte. has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DotBio Pte. raised?
DotBio Pte. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did DotBio Pte. last raise money?
DotBio Pte.'s most recent round on record is a Series A, in May 2019.
What does DotBio Pte. do?
DotBio Pte. is a biotechnology company.
Where is DotBio Pte. headquartered?
DotBio Pte. is headquartered in Singapore, Singapore.
Which VCs invest in companies like DotBio Pte.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at DotBio Pte.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like DotBio Pte.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.